Cardio3 acquires 'broad-acting' CAR-T portfolio from US firm Celdara
This article was originally published in Scrip
Executive Summary
Cardio3 BioSciences of Belgium is entering the CAR-T arena with the $10m acquisition of OnCyte, the oncology division of privately-held US biotech Celdara Medical, and its portfolio of immuno-oncology product candidates.